Resistin – a marker of cardiovascular diseases
https://doi.org/10.14341/omet201745-9
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Adipose tissue is an active endocrine organ secreting a number of hormones – adipokines. One of them is resistin, which is produced not only by adipocytes, but also by monocytes, macrophages, cardiomyocytes. Since the beginning of its discovery in 2001 the effect of this adipokine on insulin resistance has been studied. However, later his role in the initiation of inflammatory reactions, activation of the endothelium, proliferation of smooth muscle cells of the blood vessels have been researched, and therefore resistin began to be considered as a possible marker of cardiovascular pathology. This review article presents data on resistin in terms of its effect on the development and progress of cardiovascular diseases.
About the Authors
Andrey F. VerbovoySamara State Medical University
Russian Federation
Sc.D., Professor
Competing Interests:
Автор декларирует отсутствие явных и потенциальных конфликтов интересов
Irina A. Tsanava
Samara State Medical University
Russian Federation
Assistant at the Endocrinology department
Competing Interests:
Автор декларирует отсутствие явных и потенциальных конфликтов интересов
Nelly I. Verbovaya
Samara State Medical University
Russian Federation
Sc.D., Professor
Competing Interests:
Автор декларирует отсутствие явных и потенциальных конфликтов интересов
Galkin A. Rudolf
Samara State Medical University
Russian Federation
Sc.D., Professor
Competing Interests:
Автор декларирует отсутствие явных и потенциальных конфликтов интересов
References
1. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-312. https://doi.org/10.1038/35053000.
2. Kim M, Oh Jk, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45(2):270-280. https://doi.org/10.1016/j.yjmcc.2008.05.006.
3. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165(3):622-632. https://doi.org/10.1111/j.1476-5381.2011.01369.x.
4. Espinola-Klein C. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci. 2011;16(1):1663. https://doi.org/10.2741/3812.
5. Calabro P. Resistin Promotes Smooth Muscle Cell Proliferation Through Activation of Extracellular Signal-Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase Pathways. Circulation. 2004;110(21):3335-3340. https://doi.org/10.1161/01.cir.0000147825.97879.e7.
6. Verma S. Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction. Circulation. 2003;108(6):736-740. https://doi.org/10.1161/01.cir.0000084503.91330.49.
7. Skilton MR, Nakhla S, Sieveking DP, et al. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol. 2005;32(10):839-844. https://doi.org/10.1111/j.1440-1681.2005.04274.x.
8. Jung H, Park K, Cho Y, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006;69(1):76-85. https://doi.org/10.1016/j.cardiores.2005.09.015.
9. Verbovoi A.F., Skudaeva E.S., Pashentseva A.V. Urovni rezistina, adiponektina i insulinorezistentnosti u patsientov s raznoi stepen'yu narushenii uglevodnogo obmena. // Ozhirenie i metabolizm. - 2011. - T.8. - №3 - S. 57 - 60. [Skudaeva ES, Pashentseva AV, Verbovoy AF. Urovni rezistina, adiponektinai insulinorezistentnosti u patsientov s raznoystepen'yu narusheniy uglevodnogo obmena. Obesity and metabolism. 2011;(8):57-60. (In Russ.)] https://doi.org/10.14341/2071-8713-4838.
10. Chen C, Jiang J, Lu JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. AJP: Heart and Circulatory Physiology. 2010;299(1):H193-H201. https://doi.org/10.1152/ajpheart.00431.2009.
11. Gentile MT, Vecchione C, Marino G, et al. Resistin Impairs Insulin-Evoked Vasodilation. Diabetes. 2008;57(3):577-583. https://doi.org/10.2337/db07-0557.
12. Dick GM, Katz PS, Farias M, et al. Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. AJP: Heart and Circulatory Physiology. 2006;291(6):H2997-H3002. https://doi.org/10.1152/ajpheart.01035.2005.
13. Reilly MP. Resistin Is an Inflammatory Marker of Atherosclerosis in Humans. Circulation. 2005;111(7):932-939. https://doi.org/10.1161/01.cir.0000155620.10387.43.
14. Ohmori R, Momiyama Y, Kato R, et al. Associations Between Serum Resistin Levels and Insulin Resistance, Inflammation, and Coronary Artery Disease. J Am Coll Cardiol. 2005;46(2):379-380. https://doi.org/10.1016/j.jacc.2005.04.022.
15. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum Resistin (FIZZ3) Protein Is Increased in Obese Humans. J Clin Endocr Metab. 2003;88(11):5452-5455. https://doi.org/10.1210/jc.2002-021808.
16. Melone M, Wilsie L, Palyha O, et al. Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9. J Am Coll Cardiol. 2012;59(19):1697-1705. https://doi.org/10.1016/j.jacc.2011.11.064.
17. Kapralova I.Yu. Vzaimosvyaz' adipokinov i gormonal'no-metabolicheskikh pokazatelei u bol'nykh gipotireozom: Diss. … kand. med. nauk, - Samara; 2017. [Kapralova IY. Vzaimosvyaz' adipokinov i gormonal'no-metabolicheskikh pokazatelei u bol'nykh gipotireozom. [dissertation] Samara; 2017. (In Russ.)] Dostupno po: http://www.samsmu.ru/files/referats/2017/kapralova/dissertation.pdf Ssylka aktivna na 10.04.2017.
18. Petunina N.A., Al'tshuler N.E. Sravnitel'nyi analiz urovnei adiponektina, leptina, rezistina, pokazatelei lipidnogo obmena i insulinorezistentnosti pri subklinicheskom gipotireoze v zavisimosti ot nalichiya/otsutstviya zamestitel'noi terapii levotiroksinom. // Endokrinologiya: Novosti, Mneniya, Obuchenie. - 2013. - №2. - S. 27-31. [Petunina N.A., Al'tshuler N.E. Sravnitel'nyi analiz urovnei adiponektina, leptina, rezistina, pokazatelei lipidnogo obmena i insulinorezistentnosti pri subklinicheskom gipotireoze v zavisimosti ot nalichiya/otsutstviya zamestitel'noi terapii levotiroksinom. Endokrinologiya: Novosti, Mneniya, Obuchenie. 2013;(2):27-31.(In Russ.)]
19. Polonskaya Ya.V., Kashtanova E.V., Stakhneva E.M., i dr. Svyaz' gormonov zhirovoi tkani s lipidnym i uglevodnym obmenom u muzhchin s koronarnym aterosklerozom. // Ateroskleroz i dislipidemii. - 2015. - №4. - C. 46-51. [Polonskaja JaV, Kashtanova EV, Stahneva EM, et al. The relationship of hormones of adipose tissue with lipid and carbohydrate metabolism in men with coronary atherosclerosis. Ateroskleroz i dislipidemii. 2015;(4):46-51.(In Russ.)]
20. Anderson PD, Mehta NN, Wolfe ML, et al. Innate Immunity Modulates Adipokines in Humans. J Clin Endocr Metab. 2007;92(6):2272-2279. https://doi.org/10.1210/jc.2006-2545.
21. Menzaghi C, Marucci A, Antonucci A, et al. Suggestive evidence of a multi-cytokine resistin pathway in humans and its role on cardiovascular events in high-risk individuals. Sci Rep. 2017;7:44337. https://doi.org/10.1038/srep44337.
22. Wang H, Chen D-y, Cao J, et al. High Serum Resistin Level may be an Indicator of the Severity of Coronary Disease in Acute Coronary Syndrome. Chin Med Sci J. 2009;24(3):161-166. https://doi.org/10.1016/s1001-9294(09)60082-1.
23. Chu S, Ding W, Li K, et al. Plasma Resistin Associated With Myocardium Injury in Patients With Acute Coronary Syndrome. Circ J. 2008;72(8):1249-1253. https://doi.org/10.1253/circj.72.1249.
24. Hu WL, Qiao SB, Hou Q, Yuan JS. Plasma resistin is increased in patients with unstable angina. Chin Med J (Engl). 2007;120(10):871-875.
25. Burnett MS, Devaney JM, Adenika RJ, et al. Cross-Sectional Associations of Resistin, Coronary Heart Disease, and Insulin Resistance. J Clin Endocr Metab. 2006;91(1):64-68. https://doi.org/10.1210/jc.2005-1653.
26. Gruzdeva O.V., Karetnikova V.N., Akbasheva O.E., i dr. Soderzhanie lipidov, adipokinov i grelina pri razvitii insulinorezistentnosti u patsientov s infarktom miokarda. // Vestnik RAMN. - 2013. - №7. - S. 13-19 [Gruzdeva OV, Karetnikova VN, Akbasheva OE, et al. Lipid, Adipokine and Ghrelin Concentrations in Myocardial Infarction Patients with Insulin Resistance. Annals of the Russian Academy of Medical Sciences. 2013;7:13-19 (In Russ.)] https://doi.org/10.15690/vramn.v68i7.706
27. Teplyakov A.T., Akhmedov Sh.D., Suslova T.E., i dr. Vliyanie rezistina na techenie ishemicheskoi bolezni serdtsa u patsientov s sakharnym diabetom 2-go tipa. // Byulleten' sibirskoi meditsiny. - 2015. - T. 14. - №5. - C. 73-82. [Tepljakov AT, Ahmedov ShD, Suslova TE, et al. Influence of resistin on the course of ischemic heart disease in patients with type 2 diabetes mellitus. Bjulleten' sibirskoj mediciny. 2015;14(5):73-82 (In Russ.)]
28. Langheim S, Dreas L, Veschini L, et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. AJP: Heart and Circulatory Physiology. 2010;298(3):H746-H753. https://doi.org/10.1152/ajpheart.00617.2009.
29. Smirnova E.N., Shul'kina S.G. Dinamika urovnya leptina, rastvorimykh retseptorov leptina, indeksa svobodnogo leptina i rezistina pri snizhenii massy tela u bol'nykh arterial'noi gipertenziei, assotsiirovannoi s ozhireniem. // Arterial'naya gipertenziya. - 2016. - T. 22. - №4. - S. 382-388. [Smirnova EN, Shulkina SG. Dynamics of Leptin, Soluble Leptin Receptors, Free Leptin Index and Resistin in Reducing Body Weight in Patients with Arterial Hypertension Associated with Obesity. Arterial’naya Gipertenziya. 2016;22(4):382-388. (In Russ.)] https://doi.org/10.18705/1607-419x-2016-22-4-382-388.
30. Nedogoda S.V., Barykina I.N., Chalyabina T.A., i dr. Ozhirenie i arterial'naya gipertenziya. Chast' II: osobennosti antigipertenzivnoi terapii pri ozhirenii. // Kardiovaskulyarnaya terapiya i profilaktika. - 2009. - T. 8. - №1. - S. 88-98. [Nedogoda SV, Barykina IN, Chaljabina TA, et al. Obesity and arterial hypertension. Part II: features of antihypertensive therapy in obese patients. Kardiovaskuljarnaja terapija i profilaktika. 2009;8(1):88-98 (In Russ.)]
31. Tan M-S, Chang S-Y, Chang D-M, et al. Association of Resistin Gene 3′-Untranslated Region +62G→A Polymorphism with Type 2 Diabetes and Hypertension in a Chinese Population. J Clin Endocr Metab. 2003;88(3):1258-1263. https://doi.org/10.1210/jc.2002-021453.
32. Verbovoi A.F., Pashentseva A.B., Skudaeva E.C. Leptin, rezistin i insulinorezistentnost' u patsientov s SD 2 tipa. // Terapevt. - 2011. - №5. - S. 4-8.[Verbovoj AF, Pashenceva AB, Skudaeva EC. Leptin, resistin and insulinoresistance in type 2 diabetes patients. Terapevt.2011;5:4-8 (In Russ.)]
33. Zhang L, Curhan GC, Forman JP. Plasma Resistin Levels Associate with Risk For Hypertension among Nondiabetic Women. J Am Soc Nephrol. 2010;21(7):1185-1191. https://doi.org/10.1681/asn.2009101053.
34. Lezhenko G.A., Gladun E.V. Gormonal'nye markery formirovaniya arterial'noi gipertenzii u podrostkov s ozhireniem. // Prakticheskaya meditsina. - 2012. - T. 9. - №65. - S. 129-132. [Lezhenko GA, Gladun EV. The hormonal markers of formation of arterial hypertension in obese adolescents. Prakticheskaja medicina. 2012;9(65):129-132 (In Russ).]
35. Verbovoi A.F., Mitroshina E.V., Dolgikh Yu.A. Adipokiny, insulinorezistentost' i aktivnost' simpato-adrenalovoi sistemy u yunoshei s ozhireniem, manifestirovavshim v pubertatnyi period. // Ozhirenie i metabolizm. - 2012. - № 2. - S. 49-52. [Verbovoy AF, Mitroshina EV, Dolgih YA. Adipokiny, insulinorezistentnost' i aktivnost' simpato-adrenalovoy sistemy u yunoshey s ozhireniem, manifestirovavshim v pubertatnyy period. Obesity and metabolism. 2012; (2):49-52. (In Russ.)] https://doi.org/10.14341/omet2012249-52.
36. Hsu B-G, Lee C-J, Yang C-F, et al. High serum resistin levels are associated with peripheral artery disease in the hypertensive patients. BMC Cardiovasc Disord. 2017;17(1). https://doi.org/10.1186/s12872-017-0517-2.
37. Ermakova M.A., Shpagina L.A. Vzaimosvyaz' markerov endotelial'noi disfunktsii rezistina i adiponektina pri arterial'noi gipertenzii v usloviyakh vysokogo professional'nogo riska. // Meditsina i obrazovanie v Sibiri. - 2014. - №2 [Ermakova MA, Shpagina LA. Vzaimosvyaz' markerov endotelial'noi disfunktsii rezistina i adiponektina pri arterial'noi gipertenzii v usloviyakh vysokogo professional'nogo riska. Meditsina i obrazovanie v Sibiri. 2014;(2). (In Russ.)]
38. Dobrin JS, Lebeche D. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert Rev Cardiovasc Ther. 2014;8(3):373-391. https://doi.org/10.1586/erc.10.17.
39. Bobbert P, Jenke A, Bobbert T, et al. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail. 2012;14(11):1265-1275. https://doi.org/10.1093/eurjhf/hfs111.
40. Dolgikh Yu.A. Rol' leptina i rezistina v razvitii insulinorezistentnosti u yunoshei s ozhireniem, manifestirovavshem v pubertatnyi period. Diss. … kand. med. nauk. - Samara, 2013. [Dolgih JA. Rol' leptina i rezistina v razvitii insulinorezistentnosti u junoshej s ozhireniem, manifestirovavshem v pubertatnyj period. [dissertation] Samara; 2013.(In Russ).] Dostupno po http://medical-diss.com/medicina/rol-leptina-i-rezistina-v-razvitii-insulinorezistentnosti-u-yunoshey-s-ozhireniem-manifestirovavshim-v-pubertatnyy-period Ssylka aktivna na 10.04.2017.
41. Aleksandrov A.A., Shatskaya O.A., Kukharenko S.S., i dr. Diabeticheskaya kardiomiopatiya. Rezistin: kontrol' gipertrofii miokarda. Ratsional'naya farmakoterapiya v kardiologii. - 2014. - T. 10. - №5. - S. 534-539. [Aleksandrov AA, Shackaja OA, Kuharenko SS. Diabetic cardiomyopathy. Resistin: a control of a myocardial hypertrophy. Racional'naja farmakoterapija v kardiologii. 2014;10(5):534-539. (In Russ.)]
42. Pashentseva A.V. Rol' leptina i rezistina v razvitii insulinorezistentnosti u bol'nykh sakharnym diabetom 2 tipa. Diss.… kand. med. nauk. - Samara. 2012. [Pashenceva A.V. Rol' leptina i rezistina v razvitii insulinorezistentnosti u bol'nyh saharnym diabetom 2 tipa. [dissertation] Samara; 2012. (In Russ.)] Dostupno po http://medical-diss.com/medicina/rol-leptina-i-rezistina-v-razvitii-insulinorezistentnosti-u-bolnyh-saharnym-diabetom-2-tipa Ssylka aktivna na 10.04.2017.
43. Frankel DS, Vasan RS, D'Agostino RB, et al. Resistin, Adiponectin, and Risk of Heart Failure. J Am Coll Cardiol. 2009;53(9):754-762. https://doi.org/10.1016/j.jacc.2008.07.073.
Supplementary files
Review
For citations:
Verbovoy A.F., Tsanava I.A., Verbovaya N.I., Rudolf G.A. Resistin – a marker of cardiovascular diseases. Obesity and metabolism. 2017;14(4):5-9. (In Russ.) https://doi.org/10.14341/omet201745-9

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
ISSN 2306-5524 (Online)